PriceTargets.com logo

eFFECTOR Therapeutics - EFTR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.00
  • Forecasted Upside: 52,073.91%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.05 As of 07/26/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for EFTR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New eFFECTOR Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EFTR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EFTR

Analyst Price Target is $24.00
▲ +52,073.91% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for eFFECTOR Therapeutics in the last 3 months. The average price target is $24.00, with a high forecast of $24.00 and a low forecast of $24.00. The average price target represents a 52,073.91% upside from the last price of $0.05.

This chart shows the closing price for EFTR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in eFFECTOR Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$24.00Low
2/6/2024HC WainwrightBoost TargetBuy ➝ Buy$24.00Low
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$125.00Low
8/24/2023HC WainwrightInitiated CoverageBuy$125.00Low
5/26/2023Stifel NicolausUpgradeHold ➝ BuyLow
3/9/2023Credit Suisse GroupLower TargetOutperform$200.00 ➝ $175.00Low
1/6/2023Credit Suisse GroupLower TargetOutperform$250.00 ➝ $200.00Low
11/17/2022JMP SecuritiesLower TargetMarket Outperform$125.00 ➝ $50.00Low
8/15/2022Credit Suisse GroupLower Target$250.00N/A
8/11/2022JMP SecuritiesLower TargetMarket Outperform$200.00 ➝ $125.00Low
6/6/2022JMP SecuritiesReiterated RatingBuy$200.00High
4/11/2022JMP SecuritiesReiterated RatingBuy$200.00Medium
3/21/2022JMP SecuritiesReiterated RatingBuy$200.00High
3/17/2022Credit Suisse GroupLower TargetOutperform$400.00 ➝ $350.00High
1/25/2022Credit Suisse GroupLower TargetOutperform$500.00 ➝ $400.00High
1/25/2022Stifel NicolausDowngradeBuy ➝ Hold$500.00 ➝ $155.00High
1/25/2022JMP SecuritiesLower TargetMarket Outperform$825.00 ➝ $200.00High
11/8/2021Stifel NicolausUpgradeHold ➝ Buy$500.00High
10/12/2021Credit Suisse GroupInitiated CoverageOutperform$500.00Medium
10/4/2021MizuhoInitiated CoverageBuy$500.00High
9/21/2021JMP SecuritiesInitiated CoverageOutperform$825.00Medium
9/20/2021Stifel NicolausInitiated CoverageHold$500.00Low
9/13/2021Cantor FitzgeraldInitiated CoverageOverweight$1,250.00Medium
(Data available from 7/26/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/29/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
4/27/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
eFFECTOR Therapeutics logo
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Read More

Today's Range

Now: $0.05
Low: $0.05
High: $0.05

50 Day Range

MA: $0.80
Low: $0.04
High: $1.87

52 Week Range

Now: $0.05
Low: $0.03
High: $20.50

Volume

24,737 shs

Average Volume

452,466 shs

Market Capitalization

$216.20 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Frequently Asked Questions

What sell-side analysts currently cover shares of eFFECTOR Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on eFFECTOR Therapeutics in the last year: HC Wainwright.
View the latest analyst ratings for EFTR.

What is the current price target for eFFECTOR Therapeutics?

1 Wall Street analysts have set twelve-month price targets for eFFECTOR Therapeutics in the last year. Their average twelve-month price target is $24.00, suggesting a possible upside of 52,073.9%. HC Wainwright has the highest price target set, predicting EFTR will reach $24.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $24.00 for eFFECTOR Therapeutics in the next year.
View the latest price targets for EFTR.

What is the current consensus analyst rating for eFFECTOR Therapeutics?

eFFECTOR Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EFTR will outperform the market and that investors should add to their positions of eFFECTOR Therapeutics.
View the latest ratings for EFTR.

What other companies compete with eFFECTOR Therapeutics?

Other companies that are similar to eFFECTOR Therapeutics include Biodexa Pharmaceuticals, Histogen, Akanda, Ampio Pharmaceuticals and Lucy Scientific Discovery. Learn More about companies similar to eFFECTOR Therapeutics.

How do I contact eFFECTOR Therapeutics' investor relations team?

eFFECTOR Therapeutics' physical mailing address is 200 CLARENDON STREET 51ST FLOOR, BOSTON MA, 02116. The company's listed phone number is 858-925-8215 and its investor relations email address is [email protected]. The official website for eFFECTOR Therapeutics is www.locustwalkacquisitioncorp.com. Learn More about contacing eFFECTOR Therapeutics investor relations.